UK Promises ‘Competitive’ Clinical Trial Process Whatever The Brexit Outcome
The UK pharmaceutical industry has welcomed government guidance on the clinical trial regulatory landscape after Brexit, as well as a report from Cancer Research UK on the need to preserve alignment with the EU’s Clinical Trial Regulation.
You may also be interested in...
Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this its only route for evaluating new drug trial applications starting next year.
The UK insists there have been no major changes to the clinical trial environment since the country voted to leave the EU more than three years ago. It says the country continues to be an attractive location for clinical research.
The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.